Results 61 to 70 of about 6,520,232 (298)

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Circulating tumor cell profiling for precision oncology

Molecular Oncology, 2021
Analysis of circulating tumor cells (CTCs) collected from patient's blood offers a broad range of opportunities in the field of precision oncology. With new advances in profiling technology, it is now possible to demonstrate an association between the ...
Mahmoud Labib, Shana O. Kelley
doaj   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Circulating tumor cell detection and patient stay on treatment time.

, 2013
Circulating tumor cell detection and patient stay on treatment time.
Philip Z. Brohawn (448864), Laura K. Richman (448870), Robert J. Lechleider (448865), Xiaoru Chen (448863), Manuela Buzoianu (448867), Haifeng Bao (448861), Jiaqi Huang (79038), Theresa M. LaVallee (448871), Yihong Yao (94559), Jianliang Zhang (448868), Patricia A. Burke (448862), Robert S. Sikorski (448866), Xiaoqing Shi (448869)   +12 more
core   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

FEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri, Ayaka Nagasato‐Ichikawa, Keita Iida, Shuhei Kimura, Akira Imamoto, Mariko Okada   +5 more
wiley   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

Biomimetic Immuno-Magnetosomes for High-Performance Enrichment of Circulating Tumor Cells

, 2016
A novel biomimetic immuno-magnetosome (IMS) is developed by coating a leukocyte membrane (decorated with anti-epithelial cell-adhesion molecule antibody) on a magnetic nanocluster. In addition to the good stability and magnetic controllability, the IMS
Zhao, Dongxu, Yue, Hua, Wang, Shumin, Jin, Yongjie, Xie, Hai-Yan, Wei, Wei, Wang, Shuang, Gao, Xiaoyong, Qiao, Chenmeng, Ma, Guanghui, Xiong, Ke   +10 more
core   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Role of circulating tumor DNA and circulating tumor cells in breast cancer: History and updates

SAGE Open Medicine, 2022
Circulating tumor DNA, cell-free DNA, and circulating tumor cells have been at the epitome of recent research in breast cancer. These forms of liquid biopsies have been used in monitoring disease progression, estimating the risk of relapse, and response ...
Julien Chedid, Sabine Allam, Nathalie Chamseddine, Maroun Bou Zerdan, Clara El Nakib, Hazem I Assi   +5 more
doaj   +1 more source

Circulating Tumor Cells in Glioblastoma

Cancers
Glioblastoma multiforme (GBM) remains a devastating brain tumor with poor prognosis, traditionally viewed as non-metastatic. The recent detection of circulating tumor cells (CTCs) in glioblastoma challenges this view, which opens up novel opportunities for liquid biopsy in neuro-oncology.
Robert H. Eibl, Markus Schneemann
openaire   +2 more sources